Completed PHASE4 INTERVENTIONAL 4-arm NCT00256451

Endophenotype for Alcohol Misuse in Healthy Minority Populations (DEFINE)

Defining an Endophenotype for Alcohol Misuse: A Focus On Minority Populations

Sponsor: University of Pennsylvania

Conditions Healthy

Interventions Naltrexone Sham alcohol alcohol placebo

Updated 9 times since 2017 Last updated: Aug 16, 2019 Started: Nov 30, 2005 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00256451, this PHASE4 trial focuses on Healthy and remains completed. Sponsored by University of Pennsylvania, it has been updated 9 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Sep 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Sep 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Pennsylvania

Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States